行情

SVA

SVA

科兴生物
NASDAQ

实时行情|Nasdaq Last Sale

6.47
0.00
0.00%
停牌 16:00 04/24 EDT
开盘
--
昨收
6.47
最高
--
最低
--
成交量
0
成交额
--
52周最高
6.58
52周最低
6.25
市值
6.40亿
市盈率(TTM)
88.15
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Brazil Authorizes Use of Two Covid-19 Vaccines
The country’s health regulator, Anvisa, gave its approval to China’s CoronaVac and the shot developed by AstraZeneca and Oxford University.
marketwatch.com · 22小时前
Azerbaijan rolls out China-made jab for mass vaccination against COVID-19
BAKU, January 16, 2021 (Xinhua via COMTEX) -- A vaccine made by Chinese biopharmaceutical company Sinovac Biotech will be used for mass vaccination against...
Xinhua · 2天前
阿塞拜疆卫生部官员表示 阿塞拜疆订购了400万剂科兴生物新冠疫苗
云财经 · 2天前
侠客岛:多国领导人公开接种中国疫苗,意味着什么?
侠客岛 · 3天前
Philippines senators query government's preference for China vaccine after new efficacy data
Philippine senators on Friday questioned the government's preference for the Chinese COVID-19 vaccine after latest data showed it has a lower efficacy rate, saying this would not bode well for a country seeking to boost confidence in vaccines. President Rodrigo Duterte's office said on Monday it was expecting to receive next month the first batch of coronavirus shots developed by Sinovac Biotech, which at that time has not yet filed an emergency use request with local regulators. The initial shipment was part of the 25 million doses the Philippines has secured from the Chinese vaccine maker, which some senators want scrapped after new data from Brazil showing efficacy that was much lower than initially announced.
Reuters · 3天前
阿塞拜疆将于下周开始接种科兴生物疫苗
汇通网 · 3天前
Two senior managers from one of China's top vaccine companies have resigned
Sinopharm, a state-owned giant behind China's coronavirus vaccine development, announced its chairman left the board as of Tuesday.
CNBC.com · 3天前
WRAPUP 1-中国在发展中国家的疫苗推广活动中偷走了西方
China is stealing a march on Western drugmakers in the COVID-19 vaccine race in developing nations, with Indonesia and Turkey rolling out huge campaigns with a Chinese shot this week, Brazil due to follow soon, and even EU member Hungary signing up. Scientists in some Western countries say China has been too slow to publish trial data.
Reuters · 3天前
更多
财务预测
每股收益每股净资产每股现金流
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解SVA最新的财务预测,通过SVA每股收益,每股净资产,每股现金流等数据分析科兴生物近期的经营情况,然后做出明智的投资选择。
机构持股
总机构数: 34
机构持股: 2,308.56万
持股比例: 23.34%
总股本: 9,890.32万
类型机构数股数
增持
0
0
建仓
5
198
减持
3
3,493
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.43%
制药与医学研究
+0.21%
高管信息
Chairman/Chief Executive Officer/President/Secretary/Director
Weidong Yin
Chairman/Chief Executive Officer/President/Secretary/Director
WeiDong Yin
Chief Financial Officer/Vice President
Nan Wang
Vice President/Director of Sales/Director of Marketing
Xiaomei Yin
Director
Jianzeng Cao
Vice President
Qiang Gao
Director
Fung Qiu Hoi
Vice President
Jing Li
Independent Director
Simon Anderson
Director
Pengfei Li
Director
Guowei Wang
Independent Director
Shan Fu
Independent Director
Jue Lee
Independent Director
Kenneth Lee
Independent Director
Yuk Lam Lo
Independent Director
Meng Mei
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
SVA 简况
科兴控股生物技术有限公司(简称科兴)是一家生物制药控股公司。该公司主要负责研究、开发、制造和商业化针对甲型肝炎、乙型肝炎、季节性流感、血凝素5神经氨酸酶1(H5N1)和甲型流感(H1N1)大流行性流感和腮腺炎等人类传染病的疫苗。该公司的产品包括在中国处于临床和临床前发展阶段的候选疫苗。该公司主要从事传染疾病疫苗的销售、营销、制造和开发。该公司开发多种产品,包括Healive、Bilive、Anflu、Panflu、Whole Viron大流行性流感疫苗、Split Viron大流行流感疫苗、Panflu.1、RabEnd、腮腺炎疫苗、肠道病毒71(EV71)疫苗、肺炎球菌多糖疫苗、肺炎球菌结合疫苗、风疹疫苗、水痘疫苗和Sabin灭活脊髓灰质炎疫苗等。
展开
热门股票
代码
价格
涨跌幅

微牛提供Sinovac Biotech Ltd.(NASDAQ-SVA)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SVA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SVA股票基本功能。